Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
MEMANTINE HYDROCHLORIDE
SANDOZ CANADA INCORPORATED
N06DX01
MEMANTINE
10MG
TABLET
MEMANTINE HYDROCHLORIDE 10MG
ORAL
30/100
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0150423001; AHFS:
CANCELLED POST MARKET
2017-06-29
_Sandoz Memantine _ _Page 1 of 37_ PRODUCT MONOGRAPH PR SANDOZ MEMANTINE Memantine Hydrochloride Tablets, House standard 10 mg N-methyl-D-aspartate (NMDA) receptor antagonist Sandoz Canada Inc. Date of revision: August 17, 2016 145 Jules-Léger Boucherville, Quebec J4B 7K8 Submission Control No: 196426 _Sandoz Memantine _ _Page 2 of 37_ PR SANDOZ MEMANTINE Memantine Hydrochloride Tablets, House standard THERAPEUTIC CLASSIFICATION N-methyl-D-aspartate (NMDA) receptor antagonist ACTION AND CLINICAL PHARMACOLOGY Persistent activation of the central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open channel) NMDA receptor antagonist, which binds preferentially to the NMDA receptor-operated cation channels. It blocks the effects of pathologically elevated sustained levels of glutamate that may lead to neuronal dysfunction. There is no clinical evidence that memantine prevents or slows neurodegeneration or alters the course of the underlying dementing process in patients with Alzheimer’s disease. Memantine exhibits low to negligible affinity for other receptors (GABA, benzodiazepine, dopamine, adrenergic, noradrenergic, histamine and glycine) or voltage-dependent Ca 2+ , Na + or K + channels. In addition, it does not directly affect the acetylcholine receptor or cholinergic transmission, which have been implicated in the cholinomimetic side effects (e.g., increased gastric acid secretion, nausea and vomiting) seen with acetylcholinesterase inhibitors. Memantine showed antagonist effects at the 5HT 3 receptor with a potency similar to that for the NMDA receptor. _In vitro _ studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil or galantamine. PHARMACOKINETICS ABSORPTION: Orally administered memantine is completely Baca dokumen lengkapnya